Morningstar Investment Management LLC Makes New $608,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Morningstar Investment Management LLC has made a new investment of approximately $608,000 in Regeneron Pharmaceuticals, acquiring 1,159 shares during the second quarter.
• Institutional investors own around 83.31% of Regeneron's stock, with notable increases in positions from several hedge funds in recent months.
• Analysts have varying target prices for Regeneron, with the average target set at $817.88, and multiple ratings ranging from "Strong Buy" to "Sell."

Morningstar Investment Management LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,159 shares of the biopharmaceutical company's stock, valued at approximately $608,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. E Fund Management Hong Kong Co. Ltd. increased its position in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares in the last quarter. Activest Wealth Management increased its position in Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 21 shares during the period. Costello Asset Management INC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $27,000. Saudi Central Bank acquired a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $27,000. Finally, Colonial Trust Advisors acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on REGN. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 8th. Sanford C. Bernstein lifted their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research note on Wednesday, August 27th. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target on the stock. in a research report on Friday, August 1st. Canaccord Genuity Group restated a "buy" rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Finally, Truist Financial dropped their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $817.88.

Regeneron Pharmaceuticals Trading Down 1.2%

Shares of REGN stock opened at $557.73 on Tuesday. The business's fifty day moving average price is $573.67 and its 200 day moving average price is $563.46. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,024.36. The firm has a market capitalization of $59.11 billion, a PE ratio of 14.06, a P/E/G ratio of 1.80 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period in the prior year, the business posted $11.56 earnings per share. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.